Lv4
577 积分 2021-02-19 加入
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
22天前
已完结
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
22天前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
22天前
已完结
[Expert consensus on the assessment, diagnosis, and management of cardiovascular-kidney-metabolic syndrome]
30天前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
1个月前
已完结
Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults
1个月前
已完结
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
1个月前
已完结
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis
2个月前
已完结
Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
2个月前
已完结
Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes Mellitus
4个月前
已完结
皖公网安备34019202002308
